🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Noxopharm Ltd (NOX)

Sydney
Currency in AUD
Disclaimer
0.105
0.000(0.00%)
Closed
NOX Scorecard
Full Analysis
Suffers from weak gross profit margins
Fair Value
Day's Range
0.1050.105
52 wk Range
0.0510.155
Bid/Ask
0.11 / 0.10
Prev. Close
0.105
Open
0.105
Day's Range
0.105-0.105
52 wk Range
0.051-0.155
Volume
108,718
Average Volume (3m)
317,229
1-Year Change
5%
Fair Value
Unlock
Fair Value Upside
Unlock
NOX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Liquid assets exceed short term obligations
Show more

Noxopharm Ltd Company Profile

Noxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia. It primarily develops Veyonda, a formulation of idronoxil for the treatment of solid tumors. The company also develops LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions; and Sofra platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases. The company was incorporated in 2015 and is based in Glenhaven, Australia.

Employees
0
Market
Australia

Compare NOX to Peers and Sector

Metrics to compare
NOX
Peers
Sector
Relationship
P/E Ratio
−8.6x−3.1x−0.6x
PEG Ratio
−0.11−0.030.00
Price/Book
5.6x3.2x2.6x
Price / LTM Sales
12.8x10.2x3.2x
Upside (Analyst Target)
-202.5%48.4%
Fair Value Upside
Unlock−0.4%6.8%Unlock

FAQ

What Is the Noxopharm (NOX) Stock Price Today?

The Noxopharm stock price today is 0.105

What Stock Exchange Does Noxopharm Trade On?

Noxopharm is listed and trades on the Sydney stock exchange.

What Is the Stock Symbol for Noxopharm?

The stock symbol for Noxopharm is "NOX."

What Is the Noxopharm Market Cap?

As of today, Noxopharm market cap is 30.68M.

What is Noxopharm Earnings Per Share?

The Noxopharm EPS is -0.012.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.